FDA Puts Cord Blood Product Policy Into Practice
This article was originally published in The Pink Sheet Daily
Executive Summary
The New York Blood Center submitted the HemaCord BLA in response to the agency’s move to pull umbilical cord blood transplantation into the regulatory fold; the agency announced in 2009 that a BLA or IND would be required for the products after Oct. 20, 2011.
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.